EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology

SALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces expansion of its pharmaceutical development implementing its sub-micron platform technology.  The company's new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome.

The company's sub-micron technology allows for development of harmonized formulations and better absorption.  To date, the company has demonstrated initial proven success of the technology with Lorazepam in animals.  In its application for specific pharmaceutical molecules the company has been able to achieve positive results with drugs that are currently injected.  The company continues the development of its transmucosal Lorazepam Spray for the treatment of acute seizures. 

After much exploratory work the company has expanded its research to include the delivery of large molecules, such as insulin and other peptides through an intraoral route.  The delivery methods considered for intraoral insulin formulation includes liquid, semi-solid and other types of sub-micron compositions; all of which are delivered in the mouth for intraoral absorption.  Initial testing of some insulin formulations for glucose control have been conducted with successful results.  Future plans for next steps are currently being designed.

Intraoral insulin opens up the opportunity to enter into and play a role in the enormous and fast-growing diabetes and metabolic syndrome treatment markets. There are currently 347 million diabetes patients throughout the world and 36 million in the United States alone.  This diabetes product platform will be an avenue to be used by the critical masses.

"We are planning to finalize the details of the development, clinical and regulatory plan for our intraoral insulin platform soon," says Anna Gluskin, EastGate's CEO.  "This diabetes-focused development will achieve opportunities on a number of fronts—it continues to validate our sub-micron  technology; opens up opportunities to enter large blockbuster markets servicing the growing chronic diabetes patient population and provides shareholders with an exciting and value-added exit strategy," states Gluskin.

About EastGate Acquisitions Corporation

EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules.   The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements.  Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules.  The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes.   Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions.  EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development.  We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate's approach will be most beneficial for patient care.   For more information, please visit the company's website at www.EastGatePharmaceuticals.com.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:  Rose Perri 1-647-692-0652
Email:  [email protected]  
Text:  ESAQ to 87804

SOURCE EastGate Acquisitions Corporation